

Table SI. Primary antibodies

| Antibody | Clone | Procedure | Dilution | Source |
|----------|---------------|---------------|----------|--------------------------|
| CD1a | Monoclonal | No | 1:5 | Immunotech 1590 |
| CD3 | F7.2.38 | Heat, citrate | 1:50 | DAKO M7254 |
| CD4 | 4B12 | Heat, pH 9.0 | 1:150 | Novocastra NCI-I-CD4-368 |
| CD8 | C8/144B | Heat, pH 9.0 | 1:3 | DAKO N1592 |
| CD10 | 5666 | Heat, citrate | 1:80 | Novocastra |
| CD20 | L26 | None | 1:1 | DAKO H 7093 |
| CD30 | Ber-H2 | Heat, pH 7.2 | 1:8 | DAKO H7119 |
| CD45RO | UCHL1 | None | 1:4 | DAKO N1520 |
| CD45RA | 4KB5 | None | 1:40 | DAKO M0754 |
| CD56 | – | Heat, citrate | 1:1 | ZYMED 08-1152 |
| CD79a | 3CB117 | Heat, citrate | 1:4 | DAKO N1628 |
| BCL2 | 124 | Heat, pH 7.2 | 1:6 | DAKO H7124 |
| BCL6 | PG-B6p | Heat, pH 9.0 | 1:20 | DAKO M7211 |
| Ki67 | MiB-1 | Heat, pH 9.0 | 1:200 | DAKO M 7240 |
| Lamda | Polyclonal | Heat, pH 9.0 | 1:20 | DAKO H0070 |
| Kappa | Polyclonal | Heat, pH 9.0 | 1:16 | DAKO H0069 |
| CK20 | Ks 20.8 | Proteinase K | 1:200 | DAKO M7019 |
| NSE | BB5/NC/Vi-H14 | Heat, citrate | None | DAKO H7092 |
| S100 | Polyclonal | Proteinase K | 1:1200 | DAKO Z0311 |
| PCNA | PC 10 | Heat, citrate | 1:2 | DAKO H7116 |
| LCA | 2B11 | None | None | DAKO H7090 |
| CD5 | CD5/54/F6 | Heat, pH 9.0 | 1:100 | DAKO M7194 |
| CD138 | MI 15 | Heat, pH 6.1 | 1:100 | DAKO M7228 |
| FOXP1 | JC 12 | Heat, pH 6.1 | 1:100 | Alison Banham |
| MUM1 | MUM 1p | Heat, pH 6.1 | 1:50 | DAKO M7259 |

Table SII. Determination of the prognostic index (PI) according to Smith et al. (19) for primary cutaneous B-cell lymphoma (CBCL)

| CBCL-PI group | Histology | Site |
|---------------|---|--|
| IA | Any indolent (follicular, marginal-zone, small lymphocytic not otherwise specified and lymphoplasmocytic histologies) | Any |
| IB | Diffuse large cell | Favourable: head/neck, arm |
| II | Diffuse large cell, diffuse large cell and immunoblastic | Favourable: head/neck, arm Unfavourable: trunk, leg, and disseminated |
| III | Immunoblastic, diffuse large cell | Unfavourable: trunk, leg, and disseminated |

Table SIII. Frequency of disease entities from three studies (World Health Organization - European Organization for Research and Treatment of Cancer (WHO-EORTC))

| WHO-EORTC classification (2) | This study 1 January 1980–31 December 2005 (n=299) % | Bouaziz et al. (31) January 1997–December 2003 (n=203) % | WHO-EORTC 1986–2002 (n=1905) % |
|--|--|--|--------------------------------------|
| Primary cutaneous T-cell and NK-cell lymphoma | 63.2 | 75.9 | 78 |
| Mycosis fungoides | 30.9 | 43.3 | 44 |
| Folliculotropic mycosis fungoides | 0.9 | 6.9 | 4 |
| Pagetoid reticulosis | 0.6 | 0.5 | <1 |
| Granulomatous slack skin | 0.3 | 0.5 | <1 |
| Sézary syndrome | 0.9 | 7.9 | 3 |
| Primary cutaneous anaplastic large cell lymphoma | 8.3 | 3.5 | 8 |
| Lymphomatoid papulosis | 15.9 | 7.4 | 12 |
| Subcutaneous panniculitis-like T-cell lymphoma | 0.3 | 1.0 | 1 |
| Extranodal NK/T-cell lymphoma, nasal-type | 0.3 | 0.0 | <1 |
| Primary cutaneous aggressive epidermotropic CD8 ⁺ T-cell lymphoma | 0.0 | 0.5 | <1 |
| Primary cutaneous CD4 ⁺ small/medium pleomorphic T-cell lymphoma | 1.5 | 3.0 | 2 |
| Cutaneous γ/δ T-cell lymphoma | 0.3 | 0.5 | <1 |
| Primary cutaneous peripheral T-cell lymphoma, unspecified | 0.0 | 1.0 | 2 |
| Primary cutaneous B-cell lymphoma | 36.8 | 24.1 | 22 |
| Primary cutaneous marginal zone B-cell lymphoma | 9.5 | 4.9 | 7 |
| Primary cutaneous follicle centre lymphoma | 16.9 | 17.7 | 11 |
| Primary cutaneous diffuse large B-cell lymphoma, leg-type | 8.6 | 1.0 | 4 |
| Primary cutaneous diffuse large B-cell lymphoma, others | 0.0 | 0.5 | <1 |
| Precursor lymphoid neoplasm, B-cell | 0.3 | 0 | – |
| CD4 ⁺ /CD56 ⁺ haematodermic neoplasm | 0.3 | 0 | – |
| Total | 100 | 100 | 100 |

Table SIV. Prognostic factors for disease-specific survival

| Factor | Significance |
|------------------------------|------------------------------|
| Age | |
| PCBCL | Not significant ($p=0.61$) |
| PCTCL | Not significant ($p=0.77$) |
| Sex | |
| PCBCL | Not significant ($p=0.86$) |
| PCTCL | Not significant ($p=0.80$) |
| B or T-cell lineage | Not significant ($p=0.89$) |
| WHO-EORTC classification | |
| PCBCL | Significant ($p=0.004$) |
| PCTCL | Significant ($p=0.0021$) |
| Staging of mycosis fungoides | |
| T1 against T2 | Not significant |
| T2 against T3 | Significant ($p=0.04$) |
| T3 against T4 | Not significant |
| Bunn-Lamberg | Significant (0.001) |
| Staging of PCBCL | |
| PI (Smith) | Significant (0.0001) |

PCBCL: Primary cutaneous B-cell lymphoma; PCTCL: Primary cutaneous T-cell and NK-cell lymphoma; PI: prognostic index; WHO-EORTC: World Health Organization - European Organization for Research and Treatment of Cancer (WHO-EORTC).